B-cell depletion with rituximab a promising treatment for diffuse cutaneous systemic sclerosis.docVIP

van Laar Arthritis Research Therapy 2010,12:112 /content/12/2/112 EDITORIAL B-cell depletion with rituximab: a promising treatment for di? use cutaneous systemic sclerosis Jacob M van Laar* See related research by Bosello et al., /content/12/2/R54 changes in serum levels of interleukin-6 (IL-6) and BAFF Abstract (B-cell activating factor of tumor necrosis factor family). Recent preclinical and clinical studies lend support to the notion that B-cell depletion is a promising therapeutic target in patients with di?use cutaneous systemic sclerosis. A recent open-label trial provides further